Plain-English translation of NCT04144569 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications — pyrotinib and a PD-1 inhibitor — can help treat advanced non-small cell lung cancer that has a specific genetic change called HER2 insertion mutation. The study focuses on patients whose cancer did not respond well to standard chemotherapy. Researchers want to see if this medication combination is both safe and effective for this group.
Many patients with advanced lung cancer and this particular genetic mutation run out of treatment options after their first chemotherapy fails. This trial exists to find a new treatment approach that might help patients when standard options have stopped working.
You would receive the two medications together as your treatment. The study will monitor you regularly to check how well the treatment works, measure your tumor size, and watch for any side effects. You would be one of about 30 patients enrolled in this early-stage research study.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Yongchang Zhang
Enrollment target
~30 participants
Started
January 2019
Primary completion
December 2024
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongchang Zhang, MD
Hunan Province Tumor Hospital